A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

Trial Profile

A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Filanesib (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms AfFIRM
  • Sponsors Array BioPharma
  • Most Recent Events

    • 04 Oct 2017 The study has been completed in Belgium.
    • 29 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 12 Dec 2016 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top